During the last years, several studies have evaluated different molecules related to VEGF pathway in relation to clinical outcomes in patients with NSCLC treated with CPB regimen, but until now, there are no validated predictive biomarkers in the clinical setting (40). Here, VEGFA is linked to non-small cell lung carcinoma.